Mazdutide vs Survodutide

Mazdutide wins for wider availability (especially in Asia), smoother GI tolerability at clinical doses, and a more manageable titration ladder. Its fat-loss, liver-fat, and metabolic benefits reliably land just shy of survodutide but with less day-to-day nausea at the same point in the curve.

Survodutide wins for raw potency (percentage weight and hepatic fat loss in Phase 2; top-dose numbers edge out mazdutide), a stronger thermogenic profile, and faster liver-fat clearance. The trade-off is a harsher GI side effect profile (expect to take the 20+ week titration seriously) and, for non-EU/US buyers, much more limited sourcing at present.

Pick Mazdutide if:

• Access to reliable East Asian research suppliers is a priority or requried
• GI sensitivity, nausea management, or adherence is a concern (smoother titration experience)
• Goal is robust but not absolute-maximum fat loss (~14% seen in trials)
• Reducing liver fat post-cycle, or as a bulking phase cleanup, is a main priority
• Semaglutide left too much fatigue or brain fog, but you want similar appetite suppression with higher energy

Pick Survodutide if:

• Maximal bodyweight and hepatic fat loss are the target (Phase 2: ~15–19% at high dose)
• The goal is aggressive fat clearance for contest prep, visible abs, or NAFLD risk
• Previous GLP-1 experience/tolerance is high, and GI side effects can be managed
• Sourcing from Western/EU gray-market labs is feasible or preferred
• Stronger thermogenic/energy-expenditure effects are desired alongside appetite reduction